VandenBerg Amy M
Clinical Associate Professor, University of Michigan College of Pharmacy, Ann Arbor, Michigan,
Ment Health Clin. 2022 Nov 3;12(5):270-281. doi: 10.9740/mhc.2022.10.270. eCollection 2022 Oct.
There are now 9 available FDA-approved second-generation long-acting injectable antipsychotics including aripiprazole (3), olanzapine (1), paliperidone (3), and risperidone (2). These high-cost medications are commonly used with the goal of improving adherence and patient outcomes. With almost 2 decades of use, key aspects have been well studied, including population pharmacokinetics, CYP interactions and various clinical and economic outcomes. However, there are still unknowns with these medications. Issues including adherence, transition from oral antipsychotics, renal dosing, pharmacogenomics, and managing missed doses will be addressed in the context of 4 patient cases.
目前有9种已获美国食品药品监督管理局（FDA）批准的第二代长效注射用抗精神病药物，包括阿立哌唑（3种）、奥氮平（1种）、帕利哌酮（3种）和利培酮（2种）。这些高成本药物通常用于提高依从性和改善患者预后。经过近20年的使用，其关键方面已得到充分研究，包括群体药代动力学、细胞色素P450（CYP）相互作用以及各种临床和经济结果。然而，这些药物仍存在一些未知问题。将结合4个患者病例探讨包括依从性、从口服抗精神病药物转换、肾脏给药剂量、药物基因组学以及漏服药物处理等问题。
